Agenda of the HMPC meeting 17-19 November 2025
Submitted by Anonymous (not verified) on 17 November 2025 - 15:23
Agenda of the HMPC meeting 17-19 November 2025
Medicinal products for human use: monthly figures - October 2025
Submitted by Anonymous (not verified) on 17 November 2025 - 15:19
Medicinal products for human use: monthly figures - October 2025
Human medicines European public assessment report (EPAR): Isentress, raltegravir, Date of authorisation: 19/12/2007, Revision: 45, Status: Authorised
Submitted by Anonymous (not verified) on 17 November 2025 - 15:08
Human medicines European public assessment report (EPAR): Isentress, raltegravir, Date of authorisation: 19/12/2007, Revision: 45, Status: Authorised
Improved scientific advice for medicines for public health threats including antimicrobial resistance
Submitted by Anonymous (not verified) on 17 November 2025 - 13:00
Improved scientific advice for medicines for public health threats including antimicrobial resistance
Human medicines European public assessment report (EPAR): Ivabradine Anpharm, ivabradine, Date of authorisation: 08/09/2015, Revision: 11, Status: Authorised
Submitted by Anonymous (not verified) on 17 November 2025 - 13:00
Human medicines European public assessment report (EPAR): Ivabradine Anpharm, ivabradine, Date of authorisation: 08/09/2015, Revision: 11, Status: Authorised
Emergency Task Force (ETF) recommendations
Submitted by Anonymous (not verified) on 17 November 2025 - 12:57
Emergency Task Force (ETF) recommendations
Parallel scientific advice and special development aspects or product types
Submitted by Anonymous (not verified) on 17 November 2025 - 12:57
Parallel scientific advice and special development aspects or product types
Scientific advice and protocol assistance
Submitted by Anonymous (not verified) on 17 November 2025 - 12:57
Scientific advice and protocol assistance
Scientific advice for public health emergencies and threats
Submitted by Anonymous (not verified) on 17 November 2025 - 12:55
Scientific advice for public health emergencies and threats
Guidance for applicants: the ETF scientific advice that facilitates clinical trial authorisations (SA-CTA)
Submitted by Anonymous (not verified) on 17 November 2025 - 12:52
Guidance for applicants: the ETF scientific advice that facilitates clinical trial authorisations (SA-CTA)